文献速递胸部肿瘤放疗

18F-FDG PET-CT预测局部晚期NSCLC新诱导治疗后临床结局

The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
PubMed 文献 · Radiat Oncol · 2017-01-05

该回顾性研究纳入44例IIIA/IIIB期NSCLC患者,评估低剂量分次放疗联合同步化疗诱导治疗后早期代谢反应对预后的预测价值。结果显示早期代谢应答者PFS和OS均优于无应答者,早期代谢反应可预测局部区域、远处及全局PFS。

要点

  • IC-LDRT后早期PET-CT评估代谢反应可预测LA-NSCLC患者预后。
  • 早期代谢应答者PFS和OS显著优于无应答者(p≤0.01)。
  • 早期代谢反应是局部区域、远处及全局PFS的预测因素。

核心结论

  • 在LA-NSCLC患者中,仅两周期IC-LDRT后评估的18F-FDG代谢反应可预测预后。
  • 早期代谢变化评估有助于个体化治疗。
  • 包含低剂量放疗和手术的多模式方法改善了临床结局。

研究设计与样本

  • 回顾性评估44例连续IIIA/IIIB期NSCLC患者(35例男性,平均年龄66±7.8岁)。
  • 44例接受IC-LDRT(2周期化疗,40 cGy每日两次),26/44接受新辅助放化疗(CCRT:50.4Gy),20/44接受手术。
  • 18F-FDG PET-CT在基线、IC-LDRT后(早期)和CCRT后(最终)进行,采用PERCIST标准。

主要发现

  • 原发肿瘤和淋巴结SULpeak在IC-LDRT后显著下降(p=0.004,p=0.0002),CCRT后进一步下降(p=0.0006,p=0.02)。
  • 早期PET-CT时20/42(47.6%)为应答者,22/42(52.3%)为无应答者。
  • 最终PET-CT时19/23为应答者(其中12例早期应答、7例早期无应答),4/23为无应答者(均为早期无应答)。
  • 早期应答者PFS和OS优于早期无应答者(p≤0.01)。
  • 早期代谢反应预测局部区域、远处和全局PFS(p=0.02,p=0.01,p=0.005);手术预测局部区域和全局PFS(p=0.03,p=0.009)。

关键数值与推荐

  • 采用PERCIST标准:完全/部分代谢反应为应答者,稳定/进展性疾病为无应答者。
  • IC-LDRT方案:2周期化疗,40 cGy每日两次。
  • CCRT剂量:50.4Gy。

临床怎么用

  • 对LA-NSCLC患者行IC-LDRT后早期18F-FDG PET-CT评估代谢反应,可识别预后较差的无应答者。
  • 早期代谢反应结果可能指导个体化治疗调整。

局限性

  • 回顾性研究,样本量44例。
  • 仅23/42例完成最终PET-CT,存在数据缺失。
  • 需进一步前瞻性研究验证该新诱导方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with locally advanced non-small-cell lung cancer (LA-NSCLC) have poor prognosis despite several multimodal approaches. Recently, low-dose fractionated radiotherapy concurrent to the induction chemotherapy (IC-LDRT) has been proposed to further improve the effects of chemotherapy and prognosis. Until now, the predictive value of metabolic response after IC-LDRT has not yet been investigated. AIM: to evaluate whether the early metabolic response, assessed by 18F-fluoro-deoxyglucose positron emission-computed tomography (18F-FDG PET-CT), could predict the prognosis in LA-NSCLC patients treated with a multimodal approach, including IC-LDRT. METHODS: Forty-four consecutive patients (35males, mean age: 66 ± 7.8 years) with stage IIIA/IIIB NSCLC were retrospectively evaluated. Forty-four patients underwent IC-LDRT (2 cycles of chemotherapy, 40 cGy twice daily), 26/44 neo-adjuvant chemo-radiotherapy (CCRT: 50.4Gy), and 20/44 surgery. 18F-FDG PET-CT was performed before (baseline), after IC-LDRT (early) and after CCRT (final), applying PET response criteria in solid tumours (PERCIST). Patients with complete/partial metabolic response were classified as responders; patients with stable/progressive disease as non-responders. Progression free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meyer analysis; the relationship between clinical factors and survivals were assessed using uni-multivariate regression analysis. RESULTS: Forty-four out of 44, 42/44 and 23/42 patients underwent baseline, early and final PET-CT, respectively. SULpeak of primary tumour and lymph-node significantly (p = 0.004, p = 0.0002, respectively) decreased after IC-LDRT with a further reduction after CCRT (p = 0.0006, p = 0.02, respectively). At early PET-CT, 20/42 (47.6%) patients were classified as responders, 22/42 (52.3%) as non-responders. At final PET-CT, 19/23 patients were classified as responders (12 responders and 7 non-responders at early PET-CT), and 4/23 as non-responders (all non-responders at early PET-CT). Early responders had better PFS and OS than early non-responders (p ≤ 0.01). Early metabolic response was predictive factor for loco-regional, distant and global PFS (p = 0.02, p = 0.01, p = 0.005, respectively); surgery for loco-regional and global PFS (p = 0.03, p = 0.009, respectively). CONCLUSIONS: In LA-NSCLC patients, 18F-FDG metabolic response assessed after only two cycles of IC-LDRT predicts the prognosis. The early evaluation of metabolic changes could allow to personalize therapy. This multimodality approach, including both low-dose radiotherapy that increases the effects of induction chemotherapy, and surgery that removes the disease, improved clinical outcomes. Further prospective investigation of this new induction approach is warranted.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mattoli MV, Massaccesi M, Castelluccia A, et al. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy. Radiat Oncol. 2017. PMID: 28057034. doi:10.1186/s13014-016-0737-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。